Medical/Pharmaceuticals

JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA

SINGAPORE, Jan. 12, 2023 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd , a science-led healthcare company focused on commercialising novel therapies, has been granted distribution rights forCaris Life Sciences®

2023-01-12 13:02 2539

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

-  Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. -  Debiopharm is developing Debio 4126, a novel 3-month ext...

2023-01-12 06:00 2728

CGTN: TCM continues to play significant role in treating COVID-19

BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role inChina's fight against COVID-19.  As China is shifting the focus of its COVID-19 response from preventing infections to protecting people's health and preventing severe cases, the unique...

2023-01-11 23:09 3529

Verana Health Receives New Product Innovation Award from Frost & Sullivan for Its VeraQ Population Health Data Engine

VeraQ's powerful capabilities help to generate real-world evidence, advance therapeutic insights, enable quality measures reporting, enhance patient recruitment and engagement, and reduce trial costs. SAN ANTONIO, Jan. 11, 2023 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the real-world e...

2023-01-11 21:00 2164

Bio4t2 announces first patient infused with CAR-T targeting solid tumors

SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors. The CAR-T (B4t2-001) was developed from Bio4t2's PrismCore™ platform. "This first...

2023-01-11 09:00 2462

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval

GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronaryde novo lesions.

2023-01-11 09:00 3010

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2023-01-11 00:00 3293

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

TOKYO, Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' ant...

2023-01-10 21:05 2501

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

* Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market * FDA market authorization advances personalized cancer care in Asia * Clearance sets the stage for continued R&D investment into early d...

2023-01-10 21:05 2913

Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients

ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce opening of the Investigational New Drug ...

2023-01-10 21:00 2645

EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™

PROVIDENCE, R.I., Jan. 10, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2. The n...

2023-01-10 21:00 3443

Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps...

2023-01-10 21:00 2965

Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023

SAN FRANCISCO, Jan. 10, 2023 /PRNewswire/ -- Complete Genomics Inc ( https://completegenomics.mgiamericas.com/ ), a subsidiary of MGI Tech Co., Ltd. ("MGI"), today unveiled its full sequencing platforms at Biotech Showcase during JP Morgan Healthcare...

2023-01-10 20:30 2946

CSafe Bolsters Its Digital Ecosystem Launching TracSafe Data Loggers and CSafe Connect Portal

TracSafe fit-for-purpose data loggers link directly to the comprehensive CSafe Connect customer portal creating the next iteration of a progressive customer-focused digital ecosystem MONROE, Ohio, Jan. 10, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive ...

2023-01-10 20:00 3303

Sarah Otten Joins Medison Pharma as VP, GM Americas Region

Sarah Otten will lead Medison's Americas region covering Canada and Latin America. Sarah brings vast geographical expansion experience in international markets. PETACH TIKVAH, Israel and ZUG, Switzerland, Jan. 9, 2023 /PRNewswire/ -- Medison Pharma ("Medison"), a...

2023-01-10 19:54 2167

Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report

Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions Promising therapeutic developments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and breast cancer on horizon LONDON, Jan. 10, 2023 /PRNewswire/ ...

2023-01-10 16:00 1906

Appointment of Dr. David John Jeans CBE as HistoIndex's Non-Executive Chairman

SINGAPORE, Jan. 10, 2023 /PRNewswire/ -- The Board of Directors (the "Board") of HistoIndex (the "Company") would like to announce the following changes in appointments to the Board with effect from6th December 2022: (1) Mr Sim Giok Lak's decision to step down as Non-Executive Chairman of the Bo...

2023-01-10 13:01 1851

Bangkok Dusit Medical Services extends partnership with CNN to explore global health issues

HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Bangkok Dusit Medical Services Public Company Limited (BDMS), the largest healthcare network inThailand, reinforces its long-standing partnership with CNN International Commercial (CNNIC) with the sponsorship of 'Vital Signs

2023-01-10 11:24 2458

Lydus Medical Announces FDA Clearance of Vesseal™, The Microvascular Anastomosis Aid Device for Small Arteries

RA'ANANA, Israel, Jan. 10, 2023 /PRNewswire/ -- Lydus Medical is pleased to announce that the Vesseal™ has received FDA clearance 510(k). The Vesseal™ is a microvascular anastomosis suture deployment system, for standardized omni-vessel anastomoses, enabling simp...

2023-01-10 09:00 1990

Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target

NEW YORK and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of safety, tolerability, and pharmacokinetics (PK) from thePhase I clinical trial of INS018_055

2023-01-10 05:00 4007
1 ... 138139140141142143144 ... 398